355
Participants
Start Date
June 6, 2016
Primary Completion Date
October 26, 2018
Study Completion Date
October 26, 2018
1 to 4 mg tablets of GSK1278863
7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
6 mg GSK1278863 tablet
9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
Epoetin beta pegol
An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
GSK Investigational Site, Aichi
GSK Investigational Site, Aichi
GSK Investigational Site, Aichi
GSK Investigational Site, Aichi
GSK Investigational Site, Chiba
GSK Investigational Site, Chiba
GSK Investigational Site, Ehime
GSK Investigational Site, Fukui
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukushima
GSK Investigational Site, Gifu
GSK Investigational Site, Gifu
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hokkaido
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ishikawa
GSK Investigational Site, Ishikawa
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Nagano
GSK Investigational Site, Nagano
GSK Investigational Site, Numakunai
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Ōita
GSK Investigational Site, Saitama
GSK Investigational Site, Saitama
GSK Investigational Site, Shiga
GSK Investigational Site, Shizuoka
GSK Investigational Site, Tokushima
GSK Investigational Site, Tokyo
GSK Investigational Site, Tottori
GSK Investigational Site, Toyama
GSK Investigational Site, Toyama
GSK Investigational Site, Toyama
Lead Sponsor
GlaxoSmithKline
INDUSTRY